

Management Strategies for Oral Submucous Fibrosis- An Update

Running title: *Management Strategies for OSMF*

ABSTRACT:

There are plentiful management tried in OSMF, such as drugs, herbs, and Chinese medicines, but none proved to be entirely successful. So in this review, there are different management strategies tried in the management of OSMF, mechanism of action, and the dosage regimen.

KEYWORDS:

Oral Submucous Fibrosis (OSMF), potentially malignant disorder, management

INTRODUCTION:

Oral submucous fibrosis (OSMF) is a chronic disease associated with significant functional morbidity and an increased risk for malignancy. OSMF predominantly affects the Asian population and Asian migrants living in other parts of the World (Kerr et al., 2011).

The management of OSMF has been discussed previously by several authors (Jiang et al., 2009, Fedorowicz et al., 2008 & Kerr AR et al., 2011). This Review updates the different management protocols available and tried for OSMF.

VARIOUS MANAGEMENT OF OSMF IS CATEGORIZED AS FOLLOWS:

- 1. Habit counseling**
- 2. Basic regimen**
- 3. Medical management**
- 4. Physiotherapy**
- 5. Surgical management**
- 6. Laser Management**

1. Habit counseling:

- Strict discontinuance of habit
- For educating and creating awareness about the disease and its malignant potential.

2. Basic regimen:

- Going on bland food, free from chilies and pepper
- Nutritional support of high calcium, high protein, and iron supplementation along with milk can be given.

3. Medical management:

TABLE 1 Different drugs tried as management protocols are discussed in the table.

Sl no	Drugs	Mechanism of action	Duration	Dosage	Route of administration
STERIODS					
1.	Hydrocortisone (Gupta et al., 1980)	Anti-inflammatory action by inhibiting the generation of inflammatory factors and increasing the apoptosis of inflammatory cells. ²	once a week for 12 weeks	1.25 cc of injection hydrocortisone on each side	Intralesional
2.	Dexamethasone (Gupta et al., 1988)		10 weeks	4 mg	Intralesional
3.	Triamcinolone acetonide (Khanna et al., 1985)		Divided doses at 10 day intervals for a period of 2 - 3months	150-200 mg	Intralesional
4.	Triamcinolone diacetate (Borle et al., 1991)		4 weeks	10 mg/ml	Intralesional
5.	Betamethasone (Borle et al., 1991)		6 hours for 3 weeks	0.5 mg/ml	Topical
6.	Prednisolone (Laskaris et al., 2004)		2-4 weeks	20-30 mg	Systemic
7.	Steroids and antihistaminics (Kavarana et al., 1987)		3 months		
8.	Steroids and Physiotherapy	Microwave diathermy at 2450 MC/s and injection of hydrocortisone,	20-25 Watts energy for 20 minutes with		

		vitamin A and B complex. ⁵	15 sittings		
NUTRITIONAL SUPPLEMENTS					
9.	Vitamins and minerals (Gupta et al., 2004)	<p>The main action is eliminating the deficiency status and normalizing the cellular activity to prevent pathological mechanisms like carcinogenesis.</p> <p><i>The hypothesis of vitamin E mechanism</i></p> <ol style="list-style-type: none"> 1. Preventing the formation of oxidation products. 2. Free radical scavenger Prevent nerve-related pathologies 3. Increase the life span of erythrocytes 	6 weeks	Beta Carotene 50mg, vitamin A palmitate 2500 IU, vitamin E acetate, 10 IU with vitamin C, zinc, copper and manganese	oral
BIOGENIC STIMULATORS					
10.	Placental extracts (Gupta et al., 1988)	<p>It is an aqueous extract of the human placenta that contains nucleotides, enzymes, vitamins, amino acids, and steroids.</p> <p>The mechanism through "biogenic stimulation, and by increasing the recovery (Kisave et al., 2020).</p>	10 weeks	2 cc	Intralesional
11.	Papain and urea	Proteolytic enzymes breakdown the	Intra orally 2 to 3 times	100 gms urea and 100 gms papain	Biogenic stimulator and

	(Gupta et al., 1992)	inappropriate connective tissue fibrosis (Kerr et al., 2011).	daily for 15 days		keratolytic actions
		ENZYMES			
12.	Chymotrypsin (Gupta et al., 1988)	Proteolytic enzymes breakdown with inappropriate fibrosis (Kerr et al., 2011).	Biweekly	5000 IU	Intralesional
13.	Hyaluronidase(Gupta et al., 1988)		Biweekly for 10 weeks	1500 IU	Intralesional
14.	Collagenase (Lin et al 2007)		once a week for 6 weeks	1 ml of collagenase (1% solution) mixed with 1 ml of xylocaine	Intralesional
		PENETRATION ENHANCERS			
15.	Borneol (Dai et al., 2009)	Anti-fibrosis activity inhibits fibroblasts mitosis, collagen, and TIMP-1 production and can be used as a penetration enhancer (Dai et al., 2009).			Penetration enhancing effects tried in mice fibroblast
		VASODILATORS			
16.	Nylidrin hydrochloride (Sharma et al., 1987)	Nylidrin relaxes and dilates the blood vessel ensures more excellent blood supply to ischemic tissues with little or no change in the blood pressure and heart rate (Sharma et al., 1987).		6 mg	Oral

17.	Pentoxifylline (Rajendran et al., 2006)	It is a methylxanthine derivative with vasodilating properties and was envisaged to increase mucosal vascularity Rajendran et al., 2006).	3 times daily for 7 months	400mg	Oral
18.	Buflomedial hydrochloride (Lai et al., 1995)	The mechanism is through vasodilation, mild anticoagulant properties, immune modulation, and antioxidant properties have been reported (Kerr et al., 2011).	4 weeks	450 mg TID	Oral
19.	xantinol nicotinate (Singh et al., 2006)	Peripheral vasodialator	4 months	Biweekly	Intralesional
IMMUNOMODULATORS					
20.	Levamisole and vitamin A (Rao et al., 1993)	Immune modulation diminishes pro-fibrotic inflammation and enhances pro-fibrinolytic immune-mediated pathways (Kerr et al., 2011).	4 days OD for one week followed by biweekly for one month	150 mg of levamisole along with aqua sol caps 50000 iu	Oral
21.	Interferon gamma (Haque et al., 2001)	<i>IFN</i> γ is an antifibrotic cytokine.	Twice a week for 8 weeks (15 intralesional injections)	Eutectic Mixture of Local Anesthetics cream for 15 minutes then followed by application of 0.25 ml (50 mg) of	Intralesional

				IFN- γ	
		ALTERNATIVE MEDICINE			
22.	Immune milk (Tai et al., 2001)	It contains a highly active anti-inflammatory compound that suppressed the experimentally induced inflammation in animal models.	Twice a day for 3 months	45 gm	Oral
23.	Turmeric (Hastak et al., 1997)	Anti-inflammatory, antioxidant, anti-cancer properties.	3 months	Turmeric Oil (600 mg TO mixed with 3 g TE/day)	Oral
24.	Lycopene (Kumar et al., 2007)	Anticarcinogenic, antioxidant, highest physical quenching	2 months	16 mg	Oral
25.	Tea pigments and vitamins (Li et al., 1998)	The main action is by eliminating the deficiency status and normalizes the cellular activity to prevent pathological mechanisms like carcinogenesis (Kerr et al., 2011).			
26.	Mangifera indica, Withania somnifera, Daucus carota, Glycyrrhiza glabra, Vitis vinifera,	Herbal antioxidant formulation.	3 months	2 capsules	Oral

	Emblica officinalis, Yashada bhasma, oils of Triticum sativum (Singh et al., 2009)				
27.	Aloe vera (Sudarshan et al., 2012)	Antioxidant, anti-inflammatory, and immunomodulation	3 times daily for 3 months	5 mg gel	Topical
		OTHERS			
28.	Gold (Joshi SG.,1953)				With the surgical cutting of bands
29.	Glucosidorum tripterygii totorum, vitamin A and E, nicotinic acid (Liu et al., 1997)	The main action is by eliminating the deficiency status and normalizes the cellular activity to prevent pathological mechanisms like carcinogenesis (Kerr et al., 2011).			
30.	Danxuan koukang (Tan et al., 2006)	The mechanism is through vasodilation, mild anticoagulant properties, immune modulation, and antioxidant properties have been reported (Kerr et al., 2011).			
31.	salvia miltiorrhiza (Tan et al., 2006)				
32.	Iodine (Joshi SG.,1953)				Internal doses

33.	Arsenotlyphoid (Joshi SG.,1953)				Injection
34.	Turmeric and black pepper (Pipalia et al., 2016)		3 months	Turmeric 400 mg Black pepper 100 mg 2 capsules TID	Oral
35.	Nigella sativa (Pipalia et al., 2016)		3 months	500 mg 2 capsules TID	Oral
36.	Spirulina in combination with isometric exercises/threaded tapered screw/mouth stretching device (Kanjani et al., 2019)	antioxidant, anti-inflammatory and immuno-modulation	3 months	BID	Oral
37.	Pentoxifylline and garlic pearls (Jain et al., 2016)	Garlic has immunomodulation, vasodilator, antioxidant, anti-inflammatory, and chemopreventive Pentoxifylline has antifibrinolytic, immunomodulation, anti-TNF effect, and hemorheological property.	3 months	Pentoxifylline 400 mg and garlic pearls 0.25% BID	Oral

4. Physiotherapy

- Physiotherapy over the affected area to generate heat and mouth opening has been tried.

- A study in 2009 conducted on Fifty-four Nepali OSMF patients was managed for four months by randomly assigning them to 3 groups. The first group patients in the physiotherapy group were asked to do jaw exercises five times a day in which tongue spatulas were placed passively between anterior teeth, spatula number determined by comfortable mouth opening. An extra spatula was added every fifth day, but the spatula was tried on the tenth day in case of pain. The patient was subjected to analgesics 30 minutes before exercise to reduce the pain. The second group was treated with local injection of steroids, and the third group received no active treatment. The patients subjected to physiotherapy improved mouth opening compared to the other two groups (Cox et al., 2009).

5. Surgical Treatment

This form of modality is usually suggested during the severe form of OSMF and when the other forms of modality are unsuccessful.

6. Laser

A systematic review by Gondivkar SM et al. from various databases found that studies with Laser were used for stage II and III OSMF patients. Even though different Laser types and parameters were considered, all studies showed improvement in mouth opening ranging between 6.84mm to 23.7mm. Further two studies showed improvement in tongue protrusion, check flexibility, and reduction in burning sensation (Gondivkar et al., 2020).

The treatment of OSMF is still not satisfactory. Therefore, further clinical trials with newer modalities and combinations are required to manage this potentially malignant disorder and to prevent its malignant transformation.

REFERENCES:

Borle, R. M., & Borle, S. R. (1991). Management of oral submucous fibrosis: a conservative approach. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*, 49(8), 788–791.

Cox S, Zoellner H (2009). Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. *J Oral Pathol Med*; 38: 220-6.

Dai JP, Chen J, Bei YF, Han BX, Wang S (2009). Influence of borneol on primary mice oral fibroblasts: a penetration enhancer may be used in oral submucous fibrosis. *J Oral Pathol Med*. 2009; 38(3):276-81.

Fedorowicz, Z., Chan Shih-Yen, E., Dorri, M., Nasser, M., Newton, T., & Shi, L. (2008). Interventions for the management of oral submucous fibrosis. The Cochrane database of systematic reviews, (4), CD007156.

Gondivkar DSM, Gadail DAR, Sarode DSC (2020). Treatment outcomes of laser therapy in oral submucous fibrosis-a systematic review. *J Oral Biol Craniofac Res*.10(3):253-258.

Gupta DCS, Rameshwar D, Iqbal A (1992). Treatment modalities in oral submucous fibrosis: how they stand today? Study of 600 cases. *Indian J Oral Maxillofac Surg*;7: 43–47.

Gupta DS, Gupta MK, Golhar BL (1980). Oral submucous fibrosis – a clinical study and management by physiofibrolysis (MWD). *Journal Indian Dental Association*,52,375-8.

Gupta S, Reddi MVR, Harinath BC.(2004). Role of oxidative stress and antioxidants in etiopathogenesis and management of oral submucous fibrosis. *Indian Journal of Clinical Biochemistry*,19,138-14.

Gupta, D., & Sharma, S. C. (1988). Oral submucous fibrosis--a new treatment regimen. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*, 46(10), 830–833.

Haque MF, Meghji S, Nazir R, Harris M (2001). Interferon gamma (IFN- γ) may reverse oral submucous fibrosis. *J Oral Pathol Med*; 30: 12-1.

Hastak K, Lubri N, Jakhi SD (1997). Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. *Cancer Lett*; 116: 265–9.

Jain N, Annigeri RG and Pipalia PR (2016). Efficacy of garlic in conjunction with pentoxifylline in the management of oral submucous fibrosis – a preliminary study. *Int J Pharm Sci Res*; 7(12): 5017-23.

Jiang, X., & Hu, J. (2009). Drug treatment of oral submucous fibrosis: a review of the literature. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*, 67(7), 1510–1515.

Joshi SG. Submucous Fibrosis of the Palate and Pillars. *Ind J Otolaryngol* 1953; 4: 1-4.

Kanjani V., Annigeri R.G., Revanappa M.M., Rani A (2019). Efficacy of spirulina along with different physiotherapeutic modalities in the management of oral submucous fibrosis. *Ann Maxillofac Surg*;9(1):23–27.

Kavarana, N. M., & Bhathena, H. M. (1987). Surgery for severe trismus in submucous fibrosis. *British journal of plastic surgery*, 40(4), 407–409.

Kerr, A. R., Warnakulasuriya, S., Mighell, A. J., Dietrich, T., Nasser, M., Rimal, J., Jalil, A., Bornstein, M. M., Nagao, T., Fortune, F., Hazarey, V. H., Reichart, P. A., Silverman, S., & Johnson, N. W. (2011). A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. *Oral diseases*, 17 Suppl 1, 42–57.

Khanna, J. N., & Andrade, N. N. (1995). Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases. *International journal of oral and maxillofacial surgery*, 24(6), 433–439.

Kisave P, Shekhar V, Babu PS (2020). The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis. *J Family Med Prim Care*; 9(5):2469-2474.

Kumar A, Bagewadi A, Keluskar V, Singh M (2007). Efficacy of lycopene in the management of oral submucous fibrosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* ; 103: 207–13.

Lai DR, Chen HR, Lin LM, Huang YL, Tsai CC (1995). Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150-cases. *J Oral Pathol Med*; 240: 402-06.

Laskaris G (2004). *Treatment of Oral Diseases: A Concise Textbook*. Thieme: Newyork, 130.

Li X, Tang J (1998). Clinical treatment observation of tea pigment for oral submucous fibrosis. *Hua Xi Kou Qiang Yi Xue Za Zhi*. 1998; 16: 50-2.

Lin HJ, Lin JC (2007). Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. *Oral Dis*; 13: 407-13.

Liu SF, Shen TH, Tang ZG, Su HP, Luo CF (1999). On treatment of oral submucous fibrosis with glucosidum tripterygii totorum. *Beijing J Stomatol* ;7: 167–169.

Pipalia P.R., Annigeri R.G., Mehta R (2016). Clinicobiochemical evaluation of turmeric with black pepper and nigella sativa in management of oral submucous fibrosis-a double-blind, randomized preliminary study. *Oral Surg Oral Med Oral Pathol Oral Radiol*; 122(6):705–712.

Rajendran R, Rani V, Shaikh S (2006). Pentoxifylline therapy: A new adjunct in the treatment of oral submucous fibrosis. *Indian J Dent Res*; 17: 190-8.

Rao B (1993). Oral submucous fibrosis- The Davangere Study. *JIAOMR*; 4: 11-22.

Sharma JK, Gupta AK, Mukhija RD, Nigam P (1987). Clinical experience with the use of peripheral vasodilator in oral disorders. *Int J Oral Maxillofac Surg*; 16: 695-9.

Singh BP, Mittal N, Sharma V, Palani (2009). Evaluation of role of Oxitard capsules in the treatment of Oral Submucous Fibrosis. *The Antiseptic*; 106: 503-507.

Singh U (2016). Efficacy and safety of intralesional Xantinol nicotinate in the treatment of various stages of oral submucous fibrosis. *J Clin Diagn Res*; 10(10):ZC34–ZC37.

Sudarshan R, Annigeri RG, Sree Vijayabala G (2012). Aloe vera in the treatment for oral submucous fibrosis - a preliminary study. *J Oral Pathol Med*; 41(10):755-61.

Tai YS, Liu BY, Wang JT, Sun A, Kwan HW, Chiang CP (2001). Oral administration from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis. *J Oral Pathol Med*; 30: 618-25.

Tan J, Li YC, Chen A (2006). Clinical research of danxuan koukang on treatment of oral submucous fibrosis. J Traditional Chinese Med University of Hunan; 26: 41–43.

UNDER PEER REVIEW